Table 2.
The associations of PDHA1 expression levels in ovarian carcinoma and the clinical and pathologic characteristics
| PDHA1 expression in ovarian carcinoma | ||||||
|---|---|---|---|---|---|---|
|
|
||||||
| Total N | Negative | Low expression | High expression | P value | ||
| Age (years old) | 0.195 | |||||
| ≤39 | 16 | 2 (12.5%) | 9 (56.2%) | 5 (31.2%) | ||
| 40-49 | 41 | 4 (9.8%) | 26 (63.4%) | 11 (26.8%) | ||
| 50-59 | 64 | 11 (17.2%) | 44 (68.8%) | 9 (14.1%) | ||
| 60-69 | 72 | 17 (23.6%) | 43 (59.7%) | 12 (16.7%) | ||
| ≥70 | 39 | 10 (25.6%) | 26 (66.7%) | 3 (7.7%) | ||
| Missing | 16 | |||||
| Histological subtype | 0.004** | |||||
| Serous carcinoma | 163 | 36 (22.1%) | 112 (68.7%) | 15 (9.2%) | ||
| Mucinous carcinoma | 18 | 1 (5.6%) | 9 (50.0%) | 8 (44.4%) | ||
| Endometrioid carcinoma | 19 | 2 (10.5%) | 9 (47.4%) | 8 (42.1%) | ||
| Clear cell carcinoma | 11 | 0 (0%) | 9 (81.8%) | 2 (18.2%) | ||
| Mixed epithelial tumor | 11 | 2 (18.2%) | 6 (54.5%) | 3 (27.3%) | ||
| Undifferentiated tumor | 5 | 1 (20.0%) | 3 (60.0%) | 1 (20.0%) | ||
| Unclassified tumor and others | 21 | |||||
| FIGO Stage | 0.002** | |||||
| I | 28 | 1 (3.6%) | 15 (53.6%) | 12 (42.9%) | ||
| II | 18 | 3 (16.7%) | 9 (50.0%) | 6 (33.3%) | ||
| III | 117 | 19 (16.2%) | 84 (71.8%) | 14 (12.0%) | ||
| IV | 79 | 22 (27.8%) | 49 (62.0%) | 8 (10.1%) | ||
| Not staged or missing | 6 | |||||
| Histological Grade | 0.074 | |||||
| Well | 19 | 3 (15.8%) | 10 (52.6%) | 6 (31.6%) | ||
| Moderate | 62 | 10 (16.1%) | 40 (64.5%) | 12 (19.4%) | ||
| Poor | 133 | 30 (20.1%) | 90 (65.4%) | 13 (14.5%) | ||
| Not graded or missing | ||||||
**
P<0.01.